SBH vs REGN

For growth investors, Regeneron Pharmaceuticals, Inc.

(REGN) is the stronger pick with 1. 0% revenue growth year-over-year, versus -0. 4% for Sally Beauty Holdings, Inc. (SBH). Sally Beauty Holdings, Inc. (SBH) offers the better valuation at 7. 3x trailing P/E (6. 8x forward), making it the more compelling value choice. Analysts rate Regeneron Pharmaceuticals, Inc. (REGN) a "Buy" — based on 48 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Sally Beauty Holdings, Inc.

(SBH) is the cheapest at 7. 3x versus Regeneron Pharmaceuticals, Inc. at 17. 1x. On forward P/E, Sally Beauty Holdings, Inc. is actually cheaper at 6. 8x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Sally Beauty Holdings, Inc. wins at 0. 49x versus Regeneron Pharmaceuticals, Inc. 's 2. 43x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Regeneron Pharmaceuticals, Inc.

(REGN) delivered a total return of +43. 6%, compared to -45. 2% for Sally Beauty Holdings, Inc. (SBH). Over 10 years, the gap is even starker: REGN returned +91. 6% versus SBH's -53. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Regeneron Pharmaceuticals, Inc.

(REGN) is the lower-risk stock at 0. 77β versus Sally Beauty Holdings, Inc. 's 1. 42β — meaning SBH is approximately 86% more volatile than REGN relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 197% for Sally Beauty Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Regeneron Pharmaceuticals, Inc.

(REGN) is pulling ahead at 1. 0% versus -0. 4% for Sally Beauty Holdings, Inc. (SBH). On earnings-per-share growth, the picture is similar: Sally Beauty Holdings, Inc. grew EPS 32. 2% year-over-year, compared to 8. 2% for Regeneron Pharmaceuticals, Inc.. Over a 3-year CAGR, REGN leads at 5. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus 5. 3% for Sally Beauty Holdings, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 24. 9% versus 8. 9% for SBH. At the gross margin level — before operating expenses — REGN leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Sally Beauty Holdings, Inc. (SBH) is the more undervalued stock at a PEG of 0. 49x versus Regeneron Pharmaceuticals, Inc. 's 2. 43x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Sally Beauty Holdings, Inc. (SBH) trades at 6. 8x forward P/E versus 15. 3x for Regeneron Pharmaceuticals, Inc. — 8. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SBH: 28. 0% to $17. 75.

In this comparison, REGN (0.

5% yield) pays a dividend. SBH does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Regeneron Pharmaceuticals, Inc.

(REGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 77)). Both have compounded well over 10 years (REGN: +91. 6%, SBH: -53. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SBH (Consumer Cyclical) and REGN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.